ACR Convergence 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences
NBCD A/S at ACR Convergence 2026
Nov 6–11, 2026 Orlando, FL ~15k attendees Website
NBCD A/S brings 3 presentations to ACR Convergence 2026 in Orlando. Its program centres on knee osteoarthritis pain, with clinical trial results for a fixed-dose combination of apocynin and paeonol and for LEVI-04, a neurotrophin modulator. It also looks at pain flares in a knee osteoarthritis trial.
| Organization | ACR Convergence 2026 Attendance |
|---|---|
NBCD A/S Copenhagen, Denmark | |
A biotechnology company developing drug candidates for osteoarthritis and pain. | Poster Sun Nov 8 10:30am–12:30pm Poster Tue Nov 10 10:30am–12:30pm Poster Tue Nov 10 10:30am–12:30pm |
Find decision makers at NBCD A/S
Tell us what you sell and we’ll find the people at NBCD A/S most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American College of Rheumatology (ACR). Organization details are derived from the ACR’s published program and exhibitor floor plan, and each organization’s own website. Submit a correction